Rexall Drugs
According to its Franchise Disclosure Document or public business records, Rexall Drugs has 2 locations, all owned by franchisees. Public SBA loan records show 2 lenders made 2 loans to franchisees of Rexall Drugs. PeerSense calculates Rexall Drugs's score as 39 out of 100, using public SBA loan performance and recent lending activity.
What is the Rexall Drugs franchise?
Rexall Drugs is a pharmacy business that sells medicines and health products to customers.
The brand was founded in 1904 and is headquartered in Mississauga.
Loan Activity Score
39/100
SBA Default Rate
0.0%
Active Lenders
2
Franchising since 1904 · 2 locations
2
2 franchised
Proprietary PeerSense metric
FairDistinct lenders in public SBA records for Rexall Drugs
2
Total SBA loans
$140K
Average loan size
Source: public SBA 7(a) and 504 loan records through December 31, 2025
Referral fee at closing
SBA Lending Activity for Rexall Drugs
Loan Activity Score Breakdown
New or niche (1 to 2 loans)
Are lenders increasingly or decreasingly funding this brand? Growing trends score highest.
Blended default rate (recent + all time) compared to NAICS sector peers.
Quality lenders actively backing this brand, with penalty for lender pullback.
FDD availability, Item 19 disclosure, and overall data completeness.
Geographic spread of SBA funded locations across states.
SBA Lending Performance
SBA Default Rate
0.0%
vs 9.4% peer avg
SBA Loans
2
Total Volume
$0.3M
Active Lenders
2
States
2
vs. SBA Sector Average
SBA loan default rate vs. all franchises in the same NAICS sector, not limited to direct competitors
Key Highlights
Franchise Financing Resources
Data Insights
Key performance metrics for Rexall Drugs based on SBA lending data
SBA Default Rate
0.0%
9.4% below peer avg
SBA Loan Volume
2 loans
Across 2 lenders
Lender Diversity
2 lenders
Avg 1.0 loans per lender
Rexall Drugs: Deep SBA Data
Brand specific metrics derived directly from SBA 7(a) approval records: peak lending year, leading state, average loan size, and lender concentration. PeerSense computes these per brand so capital advisors and prospective franchisees can benchmark this opportunity against the rest of the franchise universe.
Peak SBA Year
1996
1 approval. The best year on record for Rexall Drugs.
Top SBA State
Texas
1 SBA financed Rexall Drugs locations, the densest operator footprint.
Average Loan Size
$140K
Median $140K. Use as a sizing anchor when modeling your own Rexall Drugs unit.
Lender Concentration
100%
Concentrated
Share of Rexall Drugs approvals captured by the top 3 SBA lenders.
Rexall Drugs's SBA lending pipeline peaked in 1996 (1 approval). Operator density is highest in Texas with 1 SBA financed locations. Average funded ticket sits at $140K, with the median at $140K. Lender mix is concentrated: the top three SBA lenders account for 100% of approvals. Credit decisions concentrate with a small group of incumbents.
Payment Estimator
Estimated Monthly Payment
$5,176
Principal & Interest only
Indicative only, as of October 1, 2026. Not a quote, commitment or offer of credit. Final pricing, leverage and terms are determined by the lender at underwriting, after full transaction materials are reviewed. PeerSense sources the file. The lender sets pricing. What these terms mean.
Locations
Rexall Drugs, unit breakdown
Explore Funding for Rexall Drugs
Our business financing consultants help connect you with the right lending partners. Referral fee paid at closing.
Or get an instant analysis
Scan Your Deal InstantlyPage Review
Reviewed by Edward L. Freeman, Founder and Managing Director, PeerSense
- PeerSense is a capital advisory firm that places commercial financing with direct capital sources; the capital source sets final terms.
- Edward L. Freeman founded PeerSense in January 2020.
- He is a Registered Franchise Consultant with Business Alliance, Inc., a credential issued in March 2022, and worked as a franchise consultant there from March 2022 to May 2023.
- His recorded experience includes a $22 million SBA construction loan, with about $16 million funded on the deal.
- In the 12 months through September 30, 2026, PeerSense tracked 912 publicly announced financings with a disclosed size of $361.32 billion. PeerSense Capital Data Report · Methodology page
Last reviewed LinkedIn profileAbout Edward Freeman